Intrinsic value of Exelixis, Inc. - EXEL

Previous Close

$19.27

  Intrinsic Value

$391.99

stock screener

  Rating & Target

str. buy

+999%

Previous close

$19.27

 
Intrinsic value

$391.99

 
Up/down potential

+999%

 
Rating

str. buy

We calculate the intrinsic value of EXEL stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 5.8

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  1,366
  2,111
  3,157
  4,581
  6,463
  8,885
  11,926
  15,660
  20,151
  25,452
  31,605
  38,641
  46,575
  55,415
  65,158
  75,794
  87,309
  99,683
  112,896
  126,928
  141,762
  157,382
  173,775
  190,934
  208,858
  227,547
  247,011
  267,261
  288,317
  310,202
Variable operating expenses, $m
  434
  668
  997
  1,444
  2,035
  2,795
  3,750
  4,923
  6,333
  7,998
  9,925
  12,134
  14,626
  17,402
  20,461
  23,802
  27,417
  31,303
  35,452
  39,859
  44,517
  49,422
  54,570
  59,959
  65,587
  71,456
  77,568
  83,928
  90,540
  97,412
Fixed operating expenses, $m
  148
  151
  155
  158
  162
  165
  169
  173
  176
  180
  184
  188
  192
  197
  201
  205
  210
  215
  219
  224
  229
  234
  239
  244
  250
  255
  261
  267
  273
  279
Total operating expenses, $m
  582
  819
  1,152
  1,602
  2,197
  2,960
  3,919
  5,096
  6,509
  8,178
  10,109
  12,322
  14,818
  17,599
  20,662
  24,007
  27,627
  31,518
  35,671
  40,083
  44,746
  49,656
  54,809
  60,203
  65,837
  71,711
  77,829
  84,195
  90,813
  97,691
Operating income, $m
  784
  1,292
  2,006
  2,979
  4,267
  5,925
  8,007
  10,565
  13,641
  17,274
  21,496
  26,318
  31,757
  37,816
  44,496
  51,787
  59,682
  68,165
  77,224
  86,845
  97,016
  107,725
  118,965
  130,731
  143,021
  155,836
  169,181
  183,067
  197,505
  212,511
EBITDA, $m
  795
  1,305
  2,023
  3,002
  4,297
  5,965
  8,059
  10,631
  13,726
  17,379
  21,621
  26,470
  31,940
  38,035
  44,753
  52,086
  60,026
  68,558
  77,669
  87,346
  97,575
  108,346
  119,651
  131,484
  143,844
  156,733
  170,155
  184,121
  198,642
  213,734
Interest expense (income), $m
  21
  1
  5
  11
  20
  33
  49
  69
  95
  127
  166
  211
  264
  324
  392
  467
  551
  642
  740
  846
  959
  1,079
  1,206
  1,339
  1,479
  1,626
  1,779
  1,939
  2,106
  2,279
  2,459
Earnings before tax, $m
  783
  1,287
  1,994
  2,959
  4,234
  5,876
  7,938
  10,469
  13,514
  17,108
  21,285
  26,054
  31,433
  37,425
  44,028
  51,237
  59,040
  67,425
  76,378
  85,886
  95,937
  106,520
  117,626
  129,252
  141,395
  154,056
  167,242
  180,961
  195,226
  210,053
Tax expense, $m
  212
  347
  538
  799
  1,143
  1,586
  2,143
  2,827
  3,649
  4,619
  5,747
  7,035
  8,487
  10,105
  11,888
  13,834
  15,941
  18,205
  20,622
  23,189
  25,903
  28,760
  31,759
  34,898
  38,177
  41,595
  45,155
  48,860
  52,711
  56,714
Net income, $m
  572
  939
  1,456
  2,160
  3,091
  4,289
  5,795
  7,643
  9,865
  12,489
  15,538
  19,020
  22,946
  27,320
  32,141
  37,403
  43,099
  49,220
  55,756
  62,697
  70,034
  77,759
  85,867
  94,354
  103,218
  112,461
  122,087
  132,102
  142,515
  153,338

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  1,336
  2,064
  3,086
  4,478
  6,318
  8,685
  11,658
  15,308
  19,698
  24,880
  30,895
  37,772
  45,528
  54,169
  63,693
  74,090
  85,346
  97,442
  110,358
  124,075
  138,575
  153,843
  169,868
  186,642
  204,162
  222,431
  241,457
  261,252
  281,835
  303,228
Adjusted assets (=assets-cash), $m
  1,336
  2,064
  3,086
  4,478
  6,318
  8,685
  11,658
  15,308
  19,698
  24,880
  30,895
  37,772
  45,528
  54,169
  63,693
  74,090
  85,346
  97,442
  110,358
  124,075
  138,575
  153,843
  169,868
  186,642
  204,162
  222,431
  241,457
  261,252
  281,835
  303,228
Revenue / Adjusted assets
  1.022
  1.023
  1.023
  1.023
  1.023
  1.023
  1.023
  1.023
  1.023
  1.023
  1.023
  1.023
  1.023
  1.023
  1.023
  1.023
  1.023
  1.023
  1.023
  1.023
  1.023
  1.023
  1.023
  1.023
  1.023
  1.023
  1.023
  1.023
  1.023
  1.023
Average production assets, $m
  112
  173
  259
  376
  530
  729
  978
  1,284
  1,652
  2,087
  2,592
  3,169
  3,819
  4,544
  5,343
  6,215
  7,159
  8,174
  9,257
  10,408
  11,624
  12,905
  14,250
  15,657
  17,126
  18,659
  20,255
  21,915
  23,642
  25,437
Working capital, $m
  157
  243
  363
  527
  743
  1,022
  1,372
  1,801
  2,317
  2,927
  3,635
  4,444
  5,356
  6,373
  7,493
  8,716
  10,041
  11,464
  12,983
  14,597
  16,303
  18,099
  19,984
  21,957
  24,019
  26,168
  28,406
  30,735
  33,156
  35,673
Total debt, $m
  94
  212
  377
  603
  901
  1,284
  1,766
  2,357
  3,068
  3,908
  4,882
  5,996
  7,253
  8,653
  10,196
  11,880
  13,703
  15,663
  17,755
  19,977
  22,326
  24,800
  27,396
  30,113
  32,952
  35,911
  38,993
  42,200
  45,535
  49,000
Total liabilities, $m
  216
  334
  500
  725
  1,023
  1,407
  1,889
  2,480
  3,191
  4,030
  5,005
  6,119
  7,375
  8,775
  10,318
  12,003
  13,826
  15,786
  17,878
  20,100
  22,449
  24,923
  27,519
  30,236
  33,074
  36,034
  39,116
  42,323
  45,657
  49,123
Total equity, $m
  1,119
  1,729
  2,586
  3,752
  5,294
  7,278
  9,770
  12,828
  16,507
  20,849
  25,890
  31,653
  38,152
  45,394
  53,375
  62,088
  71,520
  81,656
  92,480
  103,975
  116,126
  128,921
  142,349
  156,406
  171,088
  186,397
  202,341
  218,930
  236,178
  254,105
Total liabilities and equity, $m
  1,335
  2,063
  3,086
  4,477
  6,317
  8,685
  11,659
  15,308
  19,698
  24,879
  30,895
  37,772
  45,527
  54,169
  63,693
  74,091
  85,346
  97,442
  110,358
  124,075
  138,575
  153,844
  169,868
  186,642
  204,162
  222,431
  241,457
  261,253
  281,835
  303,228
Debt-to-equity ratio
  0.080
  0.120
  0.150
  0.160
  0.170
  0.180
  0.180
  0.180
  0.190
  0.190
  0.190
  0.190
  0.190
  0.190
  0.190
  0.190
  0.190
  0.190
  0.190
  0.190
  0.190
  0.190
  0.190
  0.190
  0.190
  0.190
  0.190
  0.190
  0.190
  0.190
Adjusted equity ratio
  0.838
  0.838
  0.838
  0.838
  0.838
  0.838
  0.838
  0.838
  0.838
  0.838
  0.838
  0.838
  0.838
  0.838
  0.838
  0.838
  0.838
  0.838
  0.838
  0.838
  0.838
  0.838
  0.838
  0.838
  0.838
  0.838
  0.838
  0.838
  0.838
  0.838

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  572
  939
  1,456
  2,160
  3,091
  4,289
  5,795
  7,643
  9,865
  12,489
  15,538
  19,020
  22,946
  27,320
  32,141
  37,403
  43,099
  49,220
  55,756
  62,697
  70,034
  77,759
  85,867
  94,354
  103,218
  112,461
  122,087
  132,102
  142,515
  153,338
Depreciation, amort., depletion, $m
  10
  13
  18
  23
  31
  40
  52
  67
  85
  105
  125
  152
  184
  218
  257
  299
  344
  393
  445
  500
  559
  620
  685
  753
  823
  897
  974
  1,054
  1,137
  1,223
Funds from operations, $m
  582
  953
  1,473
  2,183
  3,121
  4,330
  5,847
  7,709
  9,950
  12,594
  15,663
  19,172
  23,130
  27,539
  32,398
  37,702
  43,443
  49,613
  56,201
  63,198
  70,593
  78,380
  86,552
  95,107
  104,041
  113,358
  123,061
  133,155
  143,652
  154,561
Change in working capital, $m
  59
  86
  120
  164
  216
  279
  350
  429
  516
  610
  708
  809
  912
  1,017
  1,120
  1,223
  1,324
  1,423
  1,520
  1,614
  1,706
  1,796
  1,885
  1,973
  2,061
  2,149
  2,238
  2,329
  2,421
  2,517
Cash from operations, $m
  523
  867
  1,353
  2,019
  2,905
  4,051
  5,497
  7,280
  9,433
  11,985
  14,955
  18,363
  22,217
  26,522
  31,277
  36,479
  42,119
  48,190
  54,682
  61,584
  68,887
  76,584
  84,667
  93,133
  101,980
  111,209
  120,822
  130,827
  141,230
  152,044
Maintenance CAPEX, $m
  -3
  -5
  -8
  -12
  -18
  -25
  -35
  -47
  -62
  -79
  -100
  -125
  -152
  -184
  -218
  -257
  -299
  -344
  -393
  -445
  -500
  -559
  -620
  -685
  -753
  -823
  -897
  -974
  -1,054
  -1,137
New CAPEX, $m
  -42
  -61
  -86
  -117
  -154
  -199
  -249
  -306
  -368
  -435
  -505
  -577
  -651
  -725
  -799
  -872
  -944
  -1,015
  -1,083
  -1,151
  -1,216
  -1,281
  -1,344
  -1,407
  -1,470
  -1,533
  -1,596
  -1,661
  -1,727
  -1,795
Cash from investing activities, $m
  -45
  -66
  -94
  -129
  -172
  -224
  -284
  -353
  -430
  -514
  -605
  -702
  -803
  -909
  -1,017
  -1,129
  -1,243
  -1,359
  -1,476
  -1,596
  -1,716
  -1,840
  -1,964
  -2,092
  -2,223
  -2,356
  -2,493
  -2,635
  -2,781
  -2,932
Free cash flow, $m
  478
  801
  1,259
  1,890
  2,733
  3,827
  5,213
  6,927
  9,003
  11,471
  14,350
  17,662
  21,414
  25,613
  30,260
  35,350
  40,876
  46,831
  53,205
  59,988
  67,170
  74,744
  82,702
  91,041
  99,758
  108,853
  118,329
  128,192
  138,450
  149,113
Issuance/(repayment) of debt, $m
  82
  118
  166
  225
  298
  384
  482
  591
  711
  839
  974
  1,114
  1,256
  1,400
  1,543
  1,684
  1,823
  1,959
  2,092
  2,222
  2,349
  2,473
  2,596
  2,717
  2,838
  2,960
  3,082
  3,207
  3,334
  3,466
Issuance/(repurchase) of shares, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  82
  118
  166
  225
  298
  384
  482
  591
  711
  839
  974
  1,114
  1,256
  1,400
  1,543
  1,684
  1,823
  1,959
  2,092
  2,222
  2,349
  2,473
  2,596
  2,717
  2,838
  2,960
  3,082
  3,207
  3,334
  3,466
Total cash flow (excl. dividends), $m
  560
  918
  1,425
  2,116
  3,031
  4,210
  5,694
  7,518
  9,714
  12,310
  15,325
  18,776
  22,671
  27,013
  31,803
  37,034
  42,700
  48,791
  55,298
  62,210
  69,519
  77,217
  85,298
  93,758
  102,596
  111,813
  121,411
  131,399
  141,784
  152,579
Retained Cash Flow (-), $m
  -420
  -610
  -857
  -1,166
  -1,542
  -1,984
  -2,491
  -3,058
  -3,679
  -4,343
  -5,041
  -5,763
  -6,499
  -7,241
  -7,981
  -8,713
  -9,432
  -10,136
  -10,824
  -11,495
  -12,151
  -12,795
  -13,429
  -14,056
  -14,682
  -15,310
  -15,944
  -16,588
  -17,248
  -17,927
Prev. year cash balance distribution, $m
  588
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  728
  308
  568
  949
  1,489
  2,226
  3,203
  4,460
  6,036
  7,968
  10,284
  13,013
  16,171
  19,772
  23,821
  28,321
  33,268
  38,655
  44,474
  50,715
  57,368
  64,423
  71,870
  79,702
  87,914
  96,503
  105,468
  114,811
  124,536
  134,652
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  698
  282
  494
  782
  1,154
  1,616
  2,164
  2,787
  3,467
  4,177
  4,884
  5,553
  6,149
  6,638
  6,994
  7,197
  7,238
  7,119
  6,848
  6,444
  5,934
  5,345
  4,710
  4,059
  3,420
  2,815
  2,264
  1,776
  1,359
  1,014
Current shareholders' claim on cash, %
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ capsules are approved for progressive, metastatic medullary thyroid cancer. The third product, Cotellic, is a formulation of cobimetinib, a selective inhibitor of MEK is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a range of forms of cancer and are the subjects of broad clinical development programs. The Company's XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein.

FINANCIAL RATIOS  of  Exelixis, Inc. (EXEL)

Valuation Ratios
P/E Ratio -79.8
Price to Sales 29.3
Price to Book 62.8
Price to Tangible Book
Price to Cash Flow 27.1
Price to Free Cash Flow 27.4
Growth Rates
Sales Growth Rate 416.2%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate NaN%
Cap. Spend. - 3 Yr. Gr. Rate 0%
Financial Strength
Quick Ratio 2
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 212.4%
Interest Coverage -2
Management Effectiveness
Return On Assets -10.6%
Ret/ On Assets - 3 Yr. Avg. -37.5%
Return On Total Capital -25.2%
Ret/ On T. Cap. - 3 Yr. Avg. -55.8%
Return On Equity 933.3%
Return On Equity - 3 Yr. Avg. 715.5%
Asset Turnover 0.4
Profitability Ratios
Gross Margin 96.9%
Gross Margin - 3 Yr. Avg. 92.7%
EBITDA Margin -25.1%
EBITDA Margin - 3 Yr. Avg. -455.4%
Operating Margin -22%
Oper. Margin - 3 Yr. Avg. -417.2%
Pre-Tax Margin -36.6%
Pre-Tax Margin - 3 Yr. Avg. -506.2%
Net Profit Margin -36.6%
Net Profit Margin - 3 Yr. Avg. -506.2%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

EXEL stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the EXEL stock intrinsic value calculation we used $854 million for the last fiscal year's total revenue generated by Exelixis, Inc.. The default revenue input number comes from 0001 income statement of Exelixis, Inc.. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our EXEL stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for EXEL is calculated based on our internal credit rating of Exelixis, Inc., is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Exelixis, Inc..
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of EXEL stock the variable cost ratio is equal to 32%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $145 million in the base year in the intrinsic value calculation for EXEL stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Exelixis, Inc..

Corporate tax rate of 27% is the nominal tax rate for Exelixis, Inc.. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the EXEL stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for EXEL are equal to 8.2%.

Life of production assets of 20.8 years is the average useful life of capital assets used in Exelixis, Inc. operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for EXEL is equal to 11.5%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $1287.453 million for Exelixis, Inc. - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 300.041 million for Exelixis, Inc. is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Exelixis, Inc. at the current share price and the inputted number of shares is $5.8 billion.

RELATED COMPANIES Price Int.Val. Rating
BMY Bristol-Myers 48.27 78.06  str.buy
MRK Merck & Compan 86.57 44.01  sell
AMGN Amgen Inc. 207.73 157.83  hold
ARRY Array BioPharm 47.29 0.25  str.sell

CONTACT US      

About X-FIN       Privacy policy       Terms of use      

Copyright © X-FIN.com 2005-2019. All rigths reserved.